Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Cash & Equivalents (2020 - 2025)

Celularity has reported Cash & Equivalents over the past 6 years, most recently at $120000.0 for Q3 2025.

  • Quarterly results put Cash & Equivalents at $120000.0 for Q3 2025, down 9.77% from a year ago — trailing twelve months through Sep 2025 was $120000.0 (down 9.77% YoY), and the annual figure for FY2024 was $738000.0, up 225.11%.
  • Cash & Equivalents for Q3 2025 was $120000.0 at Celularity, down from $863000.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for CELU hit a ceiling of $73.3 million in Q3 2021 and a floor of $211.0 in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $863000.0 (2025), compared with a mean of $14.2 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 99.97% in 2021 and later soared 18007482.94% in 2022.
  • Celularity's Cash & Equivalents stood at $37.2 million in 2021, then crashed by 62.5% to $14.0 million in 2022, then crashed by 98.37% to $227000.0 in 2023, then soared by 225.11% to $738000.0 in 2024, then tumbled by 83.74% to $120000.0 in 2025.
  • The last three reported values for Cash & Equivalents were $120000.0 (Q3 2025), $863000.0 (Q2 2025), and $293000.0 (Q1 2025) per Business Quant data.